ArticleNanophotonics (Berlin, Germany)2023
Ultrasensitive label-free miRNA-21 detection based on MXene-enhanced plasmonic lateral displacement measurement.
Article in Nanophotonics (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel serum small extracellular vesicle miRNAs with multi-target RCA-CRISPR sensor for liver cancer detection.Journal of translational medicine · 2026Article
- Sensitive and accurate photoluminescent-multiphonon resonant Raman scattering dual-mode detection of microRNA-21 via catalytic hairpin assembly amplification and magnetic assistance.Mikrochimica acta · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miRNAs are small non-coding RNA molecules which serve as promising biomarkers due to their important roles in the development and progression of various cancer types. The detection of miRNAs is of vital importance to the early-stage diagnostics and prognostics of multiple diseases. However, traditional detection strategies have faced some challenges owing to the intrinsic characteristics of miRNAs including small size, short sequence length, low concentration level and high sequence homology in complex real samples. To overcome these challenges, we proposed a MXene-enhanced plasmonic biosensor for real-time and label-free detection of miRNA. By utilizing MXene nanomaterial which possesses unique characteristics including large surface area and strong carrier confinement abilities, we tuned the absorption of our plasmonic sensing substrate to reach a "zero-reflection" state and induced an extremely sharp phase change at the resonance angle. Combined with the sensing mechanism based on phase-induced lateral displacement measurement, this MXene-enhanced plasmonic biosensor can achieve a much superior sensing performance compared to traditional SPR devices. Based on this biosensing scheme, the ultrasensitive detection of target miRNA with a detection limit down to 10 fM has been successfully demonstrated. More importantly, single-base mismatched miRNA can be easily distinguished from the target miRNA according to the sensing signal. Furthermore, our plasmonic biosensor is capable of detecting miRNA in complex media such as 100 % human serum samples without compromising the detection sensitivity. This MXene-enhanced plasmonic sensing scheme has the ability of detecting miRNAs with extremely low concentration levels in complex surrounding media without the need of introducing extra labels or amplification tags, which holds great potential in various biological applications and clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.